

# Sustainability Report

<b>Sustainability Report</b>	<b>85-120</b>		
Foreword	86		
About BB Biotech AG	88		
Sustainability achievements 2025	90		
Sustainability Strategy	91		
Sustainable Development Goals (SDG)	96		
Sustainability at Board of Directors level	99	Sustainability at BB Biotech AG's portfolio level	114
Sustainability at Investment Manager level	101	Annex	119

# Foreword

Dear reader,

BB Biotech maintains a focused, high-conviction portfolio of biotech companies. Our portfolio companies develop products that address unmet medical needs, combining high profit-growth potential with a meaningful positive impact on patients and society.

We pursue a business-driven approach to sustainability, grounded in more than 30 years of experience as an engaged and responsible investment company, with a clear focus on creating long-term value for both our investors and society at large.

Over the past three decades, we have continuously sharpened our responsible investing strategy, acknowledging that this field is a dynamic and constantly evolving. Our ongoing ESG engagement with portfolio companies is therefore a continuous journey that supports learning and progress for all parties involved.

In 2025, BB Biotech's ESG profile continued to strengthen. MSCI ESG confirmed its assessment with a solid «A» rating, and BB Biotech was re-included in the SPI ESG Index. We also continued to combine responsible investing with active stewardship, voting at 22 of 24 votable meetings covering 141 resolutions. Diversity and inclusion remain a priority and our investments contribute positively to six UN Sustainable Development Goals, underlining the strong link between biotech innovation and positive societal outcomes.

In 2025 BB Biotech was re-included in the SPI ESG Index.

By embedding ESG considerations into our investment strategies, processes, and ownership practices, we believe we can strengthen long-term returns for our shareholders while contributing positively to broader society objectives.

As a leading biotech investor, we are uniquely positioned to help advance positive societal outcomes as new medicines from our portfolio companies reach patients. We prioritize investments in companies and assets that address unmet medical needs. The core mission of biotechnology is to improve health and quality of life, which continues to underpin the sector's long-term growing.

BB Biotech's portfolio companies saw a number of new approvals in 2025:

Company	Product	Treatment of
Vertex	Journavx (suzetrigine)	Moderate to severe acute pain
Argenx	Vyvgart Hytrulo Prefilled Syringe	Myasthenia gravis, chronic inflammatory demyelinating polyneuropathy
Alnylam (Partner: Sanofi)	Qfitlia (fitusiran)	Prevent or reduce the frequency of bleeding episodes in hemophilia A or B
Alnylam	Amvuttra	Transthyretin amyloidosis (ATTR) with Cardiomyopathy (ATTR-CM)
Ionis	Dawzera	Hereditary Angioedema
Vertex	VX-561	Cystic fibrosis

Looking ahead, we expect our portfolio companies to contribute to further new drug approvals, supported by robust pipelines with multiple product candidates in clinical development.

BB Biotech AG is committed to sustainability, and it remains a key priority for our Board of Directors.

We remain committed to transparent reporting on our processes and results, ensuring that our investors have the information they need to succeed.



Laura Hamill

**Chairwoman of the Sustainability and  
Governance Committee**

# About BB Biotech AG

BB Biotech AG («the company») invests through its subsidiaries (together «the Group» or also «BB Biotech») in companies in the fast growing market of biotechnology and is one of the world’s largest investors in this sector with more than 30 years of experience. The shares of BB Biotech AG are listed on the SIX Swiss Exchange and the Frankfurt Stock Exchange. Its investments are focused primarily on listed companies that are developing and commercializing novel drugs and therapies that offer sound value for the healthcare system.

Bellevue Asset Management AG is the delegated investment manager and administrator of BB Biotech AG. Bellevue Asset Management is a subsidiary of Bellevue Group AG and is regulated by the Swiss Financial Market Supervisory Authority FINMA.

Following sustainability-related information may either refer to our investment portfolio (BB Biotech as the investment vehicle) or to the corporate organisation (Bellevue Group / Bellevue Asset Management) that is managing the investment portfolio.

 Closed-end investment company founded in 1993	<p><b>96.5%</b></p> <p>Investment Level (December 31, 2025)</p>	<p><b>24</b></p> <p>Number of portfolio positions (December 31, 2025)</p>
 Stock exchange listed: in Zurich (CHF) and Frankfurt (EUR)		
 Member of the Swiss SPI, SPI Extra, SPI ESG, Swiss All Share, SPI ex SLI, SXI Life Sciences, SXI Bio+Medtech		
 Market cap of CHF 2.5 bn (Dec 31, 2025)	<p><b>-10.8%</b></p> <p>Discount to NAV (December 31, 2025)</p>	<p><b>5% dividend yield</b></p> <p>On Ø December share price (CHF 2.25 for 2025)</p>
 Long-only, fundamental, active investment strategy		
 Concentrated and benchmark agnostic (20-35 stocks)	<p><b>1.1% p.a.</b></p> <p>Management Fee (no additional performance fee)</p>	<p><b>~ CHF 3 mn</b></p> <p>Average daily liquidity (YTD 2025)</p>
 Over 30 years track record		

## Board of Directors



**Dr. Thomas von Planta**

**Chairman of the Board**

since 2019 on the Board

- Current:
- Chairman of Helvetia Baloise Holding
  - Board member of CorFinAd AG



**Dr. Clive Meanwell**

**Vice-Chairman**

since 2004

- Current:
- Chairman, Managing Partner & General Partner of Population Health Partners
  - Chairman of Civia Health and Board member of Fractyl Health and Saama Technologies



**Laura Hamill**

**Board member**

since 2022

- Current:
- Board member of Jazz Pharmaceuticals and Unchained Labs
  - Advisory Committee member of Launch Therapeutics



**Dr. Pearl Huang**

**Board member**

since 2022

- Current:
- CEO of Dunad Therapeutics
  - Board member of Waters Corporation
  - Member of the advisory committee of MIT Corporations



**Prof. Dr. Mads Krosgaard Thomsen**

**Board member**

since 2020

- Current:
- CEO of the Novo Nordisk Foundation
  - Board member of BioInnovation Institute Foundation
  - Member of the Scientific Advisory Board of Felix Pharmaceuticals



**Camilla Soenderby**

**Board member**


since 2024

- Current:
- Board member of Abivax and F2G
  - Member of Novo Advisory Group
  - Advisor to Private Equity Group EQT

## Investment Management Team

 <p><b>Dr. Christian Koch</b> Head BB Biotech Team &amp; Executive Board Member BAM (2025) joined 2014</p>	 <p><b>Gabriel Ego</b> General Counsel &amp; Corporate Secretary BB Biotech joined 2025</p>
 <p><b>Dr. Kyle Rasbach</b> Head US Research &amp; Investment Analyst joined 2025</p>	 <p><b>Dr. Maurizio Bernasconi</b> Deputy Head (2023) &amp; Investment Analyst joined 2017</p>
 <p><b>Dr. Jordan Baumhardt</b> Investment Analyst joined 2025</p>	 <p><b>Dr. Anna Guinot Aguado</b> Investment Analyst joined 2024</p>
 <p><b>Xinya Guo</b> Trading Strategist as of 1.1.2026</p>	
 <p><b>Dr. Samuel Crosset</b> AI &amp; Data Scientist joined 2020</p>	 <p><b>Dr. Olivia Woolley</b> AI &amp; Data Scientist joined 2022</p>
 <p><b>Dr. Can Buldun-Gora</b> AI &amp; Data Scientist joined 2022</p>	
 <p><b>Rachael Burri</b> Head Investor Relations joined 2025</p>	 <p><b>Inna Kolenzova</b> Chief of Staff joined 2025</p>

# Sustainability achievements 2025



# Sustainability Strategy

Sustainability is central to BB Biotech's business strategy, driving long-term success and value creation for shareholders and stakeholders alike. We aim for growth while considering environmental and societal needs. As an investment company, we are positioned to support sustainable development for the benefit of all our stakeholders.

Sustainability is integrated into our investment process as a key factor in assessing risks and opportunities during due diligence. We believe the most significant ESG aspect of medical development is the positive societal impact of novel therapeutics, as biotech companies aim to create drugs for unmet medical needs. Below are our four strategic focus areas in a sustainability context.

## Full integration of sustainability into business strategy

ESG and sustainable investing are widely recognized, and BB Biotech is committed to integrating sustainability at the Board, Investment Manager, and portfolio levels. These principles are the foundation of our responsible corporate practices, essential for creating value for our stakeholders. Guided by these values, we follow a clear and transparent ESG policy and investment guidelines that define our environmental, social, and governance standards.

## Maintaining CO<sub>2</sub> neutrality of business operations and initiating the Net-zero process

The Investment Manager remains committed to achieving net-zero emissions by 2050. In recent years, climate-related targets and measures were defined and implemented to manage and reduce the operational carbon footprint of the business. These efforts focused in particular on the main emission drivers, including business travel, commuting, heating and electricity.

As a result of the strategic and structural realignment initiated in 2025 including the expansion of the business footprint in Asia, the further strengthening of a fundamentally research-driven investment process and the ongoing development of the Investment Manager's operating model – the relevance and steering capability of the existing climate target framework were reassessed. The previous climate targets were therefore formally concluded at the end of 2025.

In 2026, the Investment Manager will define a revised set of climate-related targets that appropriately reflects the evolved business model and emission drivers and provides decision-useful metrics for managing climate-related risks and opportunities over a mid to long term horizon. As part of this methodological enhancement, a systematic monitoring of flight-related emissions will be introduced to improve transparency and steering of one of the most material emission sources.

The Investment Manager continues to manage and offset unavoidable CO<sub>2</sub> emissions through high-quality climate projects in Switzerland and was certified by Swiss Climate for the sixth consecutive year in 2025.

### Increase gender diversity and promote inclusion

BB Biotech values diversity within its Board of Directors and the Investment Management team, believing it drives business success. A culture of respect and collaboration across languages, cultures, and nationalities fosters innovation and long-term success. The diverse backgrounds, experiences, and networks of the Board members help attract qualified professionals and ensure effective oversight in the highly technical biotech field.

This diversity, along with an inclusive environment, supports investment decision-making aligned with the company’s long-term strategy. Gender diversity is reflected with three experienced women on the Board out of six board members. A formal policy requiring at least 30% representation has been implemented.

### Anchoring sustainability in the investment process

BB Biotech systematically reviews its investments for sustainability risks and compliance with fundamental human rights, following principles like the UN Global Compact. In addition to strict exclusion criteria, environmental, social, and governance (ESG) factors are integrated into the analysis of each company, using ratings from MSCI ESG Research. While investments in «ESG laggards» are allowed, they require a detailed and well-documented justification. If material ESG issues are identified, they are brought to the attention of the company’s management as part of a systematic stewardship process.

## Sustainability Governance

Effective sustainability governance is key to embedding sustainability in our business and investment practices while identifying opportunities and challenges early. This requires a clear regulatory framework for managing sustainability issues. Both the Board of Directors and the Investment Manager actively oversee sustainability governance. The Board’s Sustainability and Governance Committee, working with the Investment Management Team, ensures a robust sustainability strategy and meets at least four times a year.

#### ESG Governance structure



A sustainability working group at the Investment Manager is tasked with leading the implementation and integration of sustainability in all business areas. This working group consists of members from different business departments. It monitors current developments in the area of sustainability and anticipates their impact on the business model of BB Biotech. It supports the Board of Directors and the Sustainability and Governance Committee in the formulation and further development of the sustainability strategy. The sustainability working group is therefore also responsible for managing and implementing projects in the business units and areas of activity.

## Stakeholder Engagement and material ESG Topics

With our business model unchanged, material ESG topics remained the same as for the previous year. With respect to our continuous stakeholder dialogue, following aspects were considered during 2025:

Stakeholder	Engagement	Activities 2025	Topics
Shareholders	<ul style="list-style-type: none"> <li>• BB Biotech is in regular contact with its shareholders.</li> <li>• Throughout the year, regular dialogue with investors is maintained. In accordance with the listing rules of SIX Exchange and XETRA, important business developments are published by means of press releases or ad hoc announcements. At the same time, these announcements are published on the company's website.</li> <li>• The notices to shareholders required by Swiss company law are published in the Swiss Official Gazette of Commerce SOGC.</li> </ul>	<ul style="list-style-type: none"> <li>• Annual general meeting</li> <li>• Conferences and events</li> <li>• Roadshows/ investor meetings</li> <li>• Corporate website</li> <li>• ad hoc publications</li> <li>• Media releases</li> <li>• Annual and interim reports</li> </ul>	<ul style="list-style-type: none"> <li>• Economic performance</li> <li>• Portfolio companies</li> <li>• Sector developments</li> <li>• Macro developments</li> <li>• Share performance-Sustainability</li> </ul>
Employees at the Investment Manager	<ul style="list-style-type: none"> <li>• Employees are regularly informed about business developments, changes in the company and product updates. Communication takes place through various channels such as emails and townhall meetings.</li> <li>• The Investment Manager also conducts company-wide surveys to monitor employee satisfaction and engagement and ensure employees understand the business. Employee feedback is forwarded to management, which uses it to drive specific actions.</li> </ul>	<ul style="list-style-type: none"> <li>• Continuing education</li> <li>• Talent attraction and retention</li> </ul>	<ul style="list-style-type: none"> <li>• Safety and health</li> <li>• Sustainability</li> <li>• Strategy</li> <li>• Next Generation</li> </ul>
Analysts and Distribution partners	<ul style="list-style-type: none"> <li>• Our distribution partners are supported by a dedicated Investor Relations and Sales team. Analysts and distribution partners have regular personal contact with their key account managers and receive regular newsletters with product and business information.</li> <li>• You can sign up for the free email distribution list.</li> </ul>	<ul style="list-style-type: none"> <li>• Key Account Manager Relationships</li> <li>• One-on-one meetings</li> <li>• Conferences and events</li> <li>• Complaint handling</li> <li>• Survey</li> </ul>	<ul style="list-style-type: none"> <li>• Products</li> <li>• Sustainable products</li> <li>• Customer relationship and satisfaction</li> </ul>
Suppliers	<ul style="list-style-type: none"> <li>• BB Biotech and the Investment Manager are in constant contact with their suppliers and service providers. If possible, local suppliers and service providers are preferred. Each supplier or service provider undergoes pre-qualification to ensure compliance and correspondence is maintained throughout the business relationship to verify requirements, make payments and negotiate contracts.</li> </ul>	<ul style="list-style-type: none"> <li>• Direct dialogue</li> </ul>	<ul style="list-style-type: none"> <li>• Responsible procurement</li> <li>• Traceability</li> </ul>
Portfolio companies	<ul style="list-style-type: none"> <li>• In the interest of our shareholders, we engage with management as a professional investor.</li> <li>• Activities: Meetings with company representatives on all levels (top management, Board of Directors, IR, etc.)</li> </ul>	<ul style="list-style-type: none"> <li>• Management meetings (senior management, Board of Directors, IR)</li> <li>• Voting at general meetings</li> <li>• Exchange of experience</li> </ul>	<ul style="list-style-type: none"> <li>• Sustainability</li> <li>• Innovation</li> <li>• Cost structure</li> <li>• Capital structure</li> <li>• Corporate Governance</li> </ul>
ESG rating agencies	<ul style="list-style-type: none"> <li>• We engage with rating agencies and provide transparency in order to be fairly assessed.</li> </ul>	<ul style="list-style-type: none"> <li>• Meetings</li> <li>• Participation in survey</li> <li>• Training of employees based on feedback</li> </ul>	<ul style="list-style-type: none"> <li>• Small vs. large caps</li> <li>• Coverage</li> <li>• Rating methodology</li> </ul>
Regulator	<ul style="list-style-type: none"> <li>• BB Biotech regularly reports to regulators as part of its business and complies with rules and regulations.</li> </ul>	<ul style="list-style-type: none"> <li>• Exchange of experience</li> <li>• Events</li> <li>• Annual and interim reports</li> </ul>	<ul style="list-style-type: none"> <li>• All ESG-related topics</li> <li>• Reporting standards</li> </ul>
Media	<ul style="list-style-type: none"> <li>• Media office at the Investment Manager conducts active media relations with a high level of service. For balanced reputation management, the topic of sustainability has a high priority.</li> </ul>	<ul style="list-style-type: none"> <li>• Key Account Manager Relations</li> <li>• One-on-One meetings</li> <li>• Unofficial media roundtables</li> </ul>	<ul style="list-style-type: none"> <li>• All ESG-related topics</li> <li>• Company developments</li> <li>• Product and sector updates</li> </ul>

## Material ESG topics identified

The materiality assessment helps the Board of Directors and Investment Manager identify key sustainability issues by considering stakeholder expectations. The analysis continuously enhances sustainability management by understanding stakeholder needs and evolving material concerns. The materiality matrix guides corporate processes, identifying opportunities and risks and enabling appropriate actions.

## Materiality matrix

Throughout 2025 the key material topics have not changed vs. the prior reporting period, i.e. BB Biotech still derives eight central topics from the materiality matrix, which are taken into consideration as part of sustainability management and the strategy.

### 1. **Economic performance**

Financial solidity and delivering long-term total returns to shareholders ensure that BB Biotech AG is and remains a reliable and value-adding partner for all its stakeholders.

### 2. **CO<sub>2</sub> emissions**

Following the strategic and structural realignment of the Investment Manager, climate targets are being recalibrated, with a revised framework to be defined from 2026 onward.

### 3. **Corporate governance and business ethics**

BB Biotech recognizes that sound corporate governance and a clear management structure with defined roles and responsibilities are critical to the long-term success of the company.

### 4. **Transparency**

BB Biotech's corporate governance complies with internationally recognized standards. We disclose transparent information about our governance. This enables our stakeholders to verify the quality of the company and supports investors in their investment decisions.

### 5. **Diversity and inclusion**

Diversity and equal opportunities are part of the corporate culture practiced by BB Biotech and the delegated Investment Manager. Accordingly, we promote potential as well as skills and competencies equally among all employees across all age groups.

### 6. **Employee development and retention**


Our corporate culture is based on mutual respect and trusting cooperation. Regular feedback and development meetings, as well as recognition and appreciation of performance, are important prerequisites for the company's success.

### 7. **Employee engagement**

The Investment Manager commits to conduct a Group-wide employee engagement survey every three years to assess employee satisfaction and the need for improvement.

### 8. **Responsible investing/Sustainable products**

Our investment process implements formal ESG investment guidelines and therewith all investments are systematically reviewed for sustainability risks and breaches of elementary human rights. Besides upholding strict exclusion criteria, environmental, social and governance factors are integrated into the fundamental analysis of every company through an ESG integration process. ESG ratings compiled by the global leading ESG research provider MSCI ESG Research are incorporated in this process.



Further details on the management of material ESG topics follows in the chapters after we introduce the relevant SDGs.

# Sustainable Development Goals (SDG)

BB Biotech actively integrates ESG into its portfolio companies by engaging with management teams, voting at general meetings, and fostering dialogue. This ongoing collaboration is key to addressing ESG concerns and reflects a continuous learning process for all parties.

For listed portfolio companies, BB Biotech collects data from public platforms and ESG questionnaires. Over its more than 30-year history, the company has continually refined its approach to responsible investing, recognizing that it remains a dynamic and evolving process. Responsible investing has been central to BB Biotech since its founding in 1993.

Through investments in biotech companies, BB Biotech contributes to improving global health by supporting the development of new drugs for unmet medical needs, aligning with UN Sustainable Development Goal 3 to ensure healthy lives and well-being for all.

## SDGs at Board of Directors of BB Biotech AG and the Investment Manager level:

The five SDGs considered most relevant for BB Biotech on Board of Director and Investment Manager level are: good health and well-being (3), quality education (4), gender equality (5), decent work and economic growth (8) and climate action (13). This is where BB Biotech can have the most significant impact. Those material SDG’s are highlighted in color below:



Source: MSCI ESG Inc.

### Goal 3: Ensure healthy lives and promote well-being for all at all ages

Through our biotech expertise and investments, we aim to improve people’s health. Supporting good health and well-being is central to BB Biotech’s strategy. Providing capital and guidance to develop new drugs addressing unmet medical needs, such as rare disorders, cancer, and chronic diseases, is a priority for the Board and Investment Manager. The goal is to enhance patients’ quality of life, ideally curing diseases and benefiting society. Many portfolio companies align with UN Sustainable Goal 3, promoting health for all. By backing biotech innovation, BB Biotech advances medical research and global healthcare improvements.

Also in 2025, substantial medical progress was reflected in several FDA approvals and label extensions from BB Biotech's portfolio companies. Vertex received approval for JOURNAVX (suzetrigine), the first medicine in a new class of non-opioid analgesics to treat moderate-to-severe acute pain in adults. Alnylam delivered two key milestones: AMVUTTRA (vutrisiran) obtained a label expansion for adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), aimed at reducing cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits, and Qfitlia (fitusiran) was approved for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A or B (with or without inhibitors) in patients aged 12 years and older. Additionally, Argenx's VYVGART Hytrulo was approved in a prefilled syringe format enabling self-injection for adult patients with AChR-antibody positive generalized myasthenia gravis as well as adult patients with chronic inflammatory demyelinating polyneuropathy. Finally, Ionis received approval for DAWNZERO (donidalorsen) as a prophylactic treatment to prevent attacks of hereditary angioedema in patients aged 12 years and older.

Looking ahead, we anticipate that these companies will continue to secure approvals for several additional groundbreaking drugs.

#### Goal 4: Ensure inclusive, equitable and quality education and promote lifelong learning opportunities for all

BB Biotech encourages continuing education for all employees and promotes life-long learning.

By the end of 2024 Bellevue Asset Management introduced an employee and training directive; Bellevue empowers every employee to take advantage of training and development opportunities commensurate with their position and function and supports the personal and professional development activities of its employees. Accordingly, all training and development activities were systematically tracked and reported in 2025. The following table shows the average number of training and continuing education hours per employee (excluding webinars) completed during the reporting period.

Average hours per employee	2025
Total	15
- Male	12
- Female	22

Further social employee practices are presented below in the Sustainability at Investment Management Level section.

#### Goal 5: Achieve gender equality and empower all women and girls

BB Biotech fosters a culture of gender equality and promote a balanced mix of gender and age across all hierarchical levels and functions of the company.

#### Goal 8: Promote inclusive and sustainable economic growth, employment and decent work for all

BB Biotech and its delegated Investment Manager offer attractive, family-friendly working condition, promotes diversity, has a competitive salary policy with equal pay for women and men, and is committed to the training and development of its employees.

#### Goal 13: Take urgent action to combat climate change and its impacts

BB Biotech and its delegated Investment Manager ensure that responsible operational ecology contributes to CO<sub>2</sub> reduction. Necessary operational emissions that cannot be

further reduced are compensated for by purchasing CO<sub>2</sub> emission certificates in the amount of the greenhouse gas emissions emitted each year ensuring our CO<sub>2</sub> neutrality commitment.

## SDGs at portfolio level:

Portfolio level relates to the portfolio companies that BB Biotech are invested in. At the portfolio level UN SDG's are considered in order to derive the proportion of «sustainable investments» (c.f. also chapter «Proportion of ESG investments»). The concept of «Sustainable investments» introduces a positive contribution to an environmental and/or a social objective while not significantly harming any of these objectives. Furthermore, the portfolio companies must apply practices of good corporate governance.

ESG research provider MSCI ESG measures the target contribution of companies to each of the SDGs and categorizes them as «strongly aligned», «aligned», «neutral», «misaligned» and «strongly misaligned». A positive contribution to an environmental or social objective hence requires a company to exhibit a positive alignment with at least one of the 17 UN SDGs and at the same time not negatively influence any other SDG.

As at December 31, 2025, BB Biotech AG's investment portfolio exhibits a share of 58.7% in sustainable investments. Thereby, the portfolio contributes to the following 6 UN SDGs that are marked in colour:



Source: MSCI ESG Inc. United Nations

Some of BB Biotech's portfolio companies positively contribute to UN SDG No.1 (No Poverty), No.3 (Good Health & Well-Being), No.5 (Gender Equality), No.7 (Affordable and Clean Energy), No.9 (Industry, Innovation and Infrastructure) and No.13 (Climate Action). Innovative Biotech companies play a key role in contributing to the underlying objectives of "Good Health & Well-Being".

According to MSCI ESG's SDG alignment methodology, the following portfolio holdings are positively aligned with the narrowly defined goals under UN SDG No.3 (Good Health & Well-Being): Alnylam Pharmaceuticals, Amicus Therapeutics, Argenx, Ionis Pharmaceuticals, Krystal Biotech, Neurocrine Biosciences, Vertex Pharmaceuticals,

# Sustainability at Board of Directors level

Sustainability at the Board of Directors level focuses primarily of the investment strategy, the organization of the group and the guidelines and instructions to the delegated investment manager Bellevue Asset Management AG.

## Economic performance

The economic performance is essential for creating long-term value for our stakeholders with a portfolio of diversified biotech companies.

In terms of portfolio size and market capitalization, BB Biotech is one of the largest biotech investors globally. The annual average performance of BB Biotech's shares since inception in 1993 is 10.2%.

<b>BB BIOTECH (SIX)</b>	
<b>CHF 44.95</b>	
31.12.2025	
Share Price Performance YTD	<b>34.2%</b>
Market capitalisation	<b>CHF 2.5 bn</b>
Net Asset Value (NAV)	<b>CHF 50.40</b>

<b>BB BIOTECH (XETRA)</b>	
<b>EUR 48.55</b>	
31.12.2025	
Share Price Performance YTD	<b>37.0%</b>
Market capitalisation	<b>EUR 2.7 bn</b>
Net Asset Value (NAV)	<b>EUR 54.15</b>

## Corporate Governance and business ethics

BB Biotech emphasizes that both its internal processes and those managed by the Investment Manager uphold compliance, data protection, stakeholder engagement, and good business practices. The Board acknowledges its responsibility for the environmental, social, and governance (ESG) impact of its activities and integrates corporate governance as a core aspect of its operations.

Corporate governance policies are tailored to the company's size and complexity, with transparency ensured through publicly available documents, including the articles of incorporation, organizational regulations, and committee charters. The Corporate Governance report complements the annual report, detailing governance policies and their implementation.

As a company listed on Swiss and German stock exchanges, BB Biotech adheres to the respective regulations. In 2022, the Board established a «Sustainability and Governance Committee», defining its roles, responsibilities, and charter.

## Diversity, equal opportunities and non-discrimination

We are of the belief that diversity and inclusion, and people with different backgrounds, competencies and perspectives are key components to long-term success. BB Biotech's focus is on having a diverse Board of Directors whilst ensuring that they also have the relevant experience to oversee investments in the field of biotechnology. The Board of Directors is well diversified in terms of age, gender, expertise and geographical location. The Board of Directors conducts periodically salary benchmarks to ensure competitive and equal compensation. A policy on these aspects is accessible on [www.bbbiotech.com](http://www.bbbiotech.com).

## Transparency

BB Biotech's environment, social and governance (ESG) performance is reviewed on a regular basis by independent ESG rating agencies. Whereas we welcome the feedback from and collaboration with these important stakeholders it is also a learning process for both parties as investment companies structurally do not fit into the rating agencies' current measures. Following a temporary exclusion earlier in the year due to revised index inclusion criteria, BB Biotech AG was re-included in the SPI ESG Index in Switzerland in September 2025. In addition, in December 2025, MSCI ESG confirmed its assessment of BB Biotech AG with a solid A rating.

These developments underline the continued strengthening of BB Biotech AG's ESG profile and support enhanced ESG visibility among international investors, particularly those requiring ESG coverage by leading sustainability rating agencies.

The ratings and feedback provided by various ESG rating agencies are one of the factors that are taken into consideration when continuously aiming at improving BB Biotech's ESG performance – and there is a commitment by the Board of Directors to further improve going forward.

## Responsible investing

BB Biotech's Board of Directors establishes the investment strategy and guidelines for the investment manager, incorporating ESG dimensions into the process. Investment decisions are made by the Investment Management Team at Bellevue Asset Management AG.

# Sustainability at Investment Manager level

Independent – entrepreneurial – committed

Operational corporate sustainability matters have to be evaluated from the perspective of its delegated investment manager and administrator, Bellevue Asset Management AG.

## Environmental practices

Within the framework of our work processes, we attach importance to environmentally friendly practices and ensure this in particular with the following measures:

### CO<sub>2</sub> emissions

Bellevue Group was certified by the independent specialist «Swiss Climate AG» for the sixth time in 2025 (based on 2021 values). By purchasing CO<sub>2</sub> emission certificates equivalent to our annual greenhouse gas emissions, we support projects that reduce emissions by the same amount. This year, we have chosen a project focusing on «climate protection and sustainable management in Swiss forests.» The project ensures CO<sub>2</sub> storage and sustainable forest management in the canton of Schwyz. This protects the climate, preserves biodiversity in Swiss forests, and enables the production of energy wood for renewable energy production.

### Measurement of environmental indicators

The environmental indicators were calculated for the sixth time in 2025 on the basis of the 2021 financial year. The 2020 balance with normalized data in the categories commuting and business flights will be used as a reference balance to assess the efficiency of the measures implemented as part of the climate policy and to verify improvements in the CO<sub>2</sub> balance.

Total emissions (in t CO <sub>2</sub> )	Base year*	2025	2024	2023
CO <sub>2</sub> -emissions scope 1 <sup>1)</sup>	32	7	12	10
CO <sub>2</sub> -emissions scope 2 <sup>2)</sup>	44	7	10	23
CO <sub>2</sub> -emissions scope 3 <sup>3)</sup>	725	717	581	575
<b>Total CO<sub>2</sub>-emissions</b>	<b>801</b>	<b>731</b>	<b>603</b>	<b>608</b>
CO <sub>2</sub> -emissions/full-time position	8.2	8.9	6.9	6.1

\* Base year: 2020 adjusted for COVID-19 effects (travel / home office).

<sup>1)</sup> Scope 1: Direct greenhouse gas emissions

<sup>2)</sup> Scope 2: Indirect energy-related greenhouse gas emissions

<sup>3)</sup> Scope 3: Energy supply (energy-related emissions not received in scope 1 or 2): business travel (external vehicles), commuting, IT equipment, paper, print jobs, waste, water

Source: CO<sub>2</sub> Report for Bellevue Group AG issued by Swiss Climate AG (2023, 2024,2025)

As Bellevue is active in the financial sector, its Scope 1 and Scope 2 emissions are rather low. Areas of focus are heating, electricity and business travel with company cars. Most of its CO<sub>2</sub> emissions relate to Scope 3 emissions and are mainly attributed to business travel and commuting. In 2020 and 2021, action to prevent the spread of the coronavirus led to a sharp reduction in business air travel (air travel) and commuting travel. From 2022 on, CO<sub>2</sub> emissions in these two areas has increased significantly, but are still below pre-pandemic levels.

## Total emissions at a glance

Total emissions (in t CO <sub>2</sub> )	Base year*	2025	2024	2023
CO <sub>2</sub> -emissions scope 1 <sup>1)</sup>	32	7	12	10
Heating	27	6	6	7
Business trips	5	1	6	3
CO <sub>2</sub> -emissions scope 2 <sup>2)</sup>	44	7	10	23
Electricity	26	7	4	15
Heating	18	–	6	8
CO <sub>2</sub> -emissions scope 3 <sup>3)</sup>	725	717	581	575
Energy supply	20	7	13	10
Business trips	499	639	471	468
Commuting	186	60	70	90
IT equipment	14	8	23	2
other	6	3	4	5
<b>Total emissions</b>	<b>801</b>	<b>731</b>	<b>603</b>	<b>608</b>
Emissions Total / FTE (t CO <sub>2</sub> /FTE)	8.2	8.9	6.9	6.1

\* Base year: 2020 adjusted for COVID-19 effects (travel / home office).

<sup>1)</sup> Scope 1: Direct greenhouse gas emissions

<sup>2)</sup> Scope 2: Indirect energy-related greenhouse gas emissions

<sup>3)</sup> Scope 3: Energy supply (energy-related emissions not received in scope 1 or 2): business travel (external vehicles), commuting, IT equipment, paper, print jobs, waste, water

Source: CO<sub>2</sub> Report for Bellevue Group AG issued by [Swiss Climate AG](#) (2023, 2024, 2025)

## Energy consumption

Energy-efficient devices are prioritized when purchasing equipment like computers, monitors, and printers. Automated energy controls are set to put IT components into standby mode based on predefined schedules. Lighting is used only when the buildings are occupied, and additional energy-consuming devices, such as air conditioners or radiators, are operated only as needed and turned off immediately after use.

## Transportation and mobility

Our locations are very easy to reach by public transport. Employees are motivated to travel by public transport. The company supports this through financial support by providing a half-fare Travelcard of Swiss public transport free of charge to all employees. Parking spaces are not subsidized and are charged at full market rates.

Due to our global investment strategies and distribution activities with employees at different locations, international contacts are important. All office locations have a video conferencing infrastructure. Most of the meetings are through telephone and video conferencing as a substitute for physical meetings to limit travel. Where possible and appropriate, we substitute air travel with public transportation such as train travel and coordinate joint site visits.

## Procurement process

When procuring materials, furniture, food, etc., we consider local suppliers and local products whenever possible. Likewise, when selecting suppliers and service providers, their environmental practices are taken into account. In the procurement of furniture and other office materials, attention is paid to durability.

## Waste management and recycling

Systems are in place at all office locations to collect and recycle a wide range of materials, including cardboard, PET, glass, paper, batteries and IT equipment. We separate waste and dispose of it properly. We take care at the procurement stage to avoid excessive waste or other unnecessary environmental impact (e.g. use of washable dishes instead of disposable cups/plates). In addition, water filtering devices are installed to reduce PET bottle consumption. Paper consumption is a significant resource for a service company. We take appropriate measures to ensure that paper consumption is constantly reduced and can be replaced by other means (e.g. customer presentations on notebooks/tablets instead of printed handouts, video calls for customer meetings, annual reports printed on FSC paper, shipping only on request). Print programs are initialized so that printouts are two-page and black and white by default.

## Key climate-relevant memberships

In 2025 Bellevue Group was again certified by the Swiss Climate Label. In addition, Bellevue Asset Management benefits from its membership with Swiss Sustainable Finance (SSF) to support its mission to strengthen Switzerland's position as a leading voice and player in the field of sustainable finance and thus contribute to a sustainable and prosperous economy.



## TCFD

The uniform and transparent rules for disclosing the financial climate risks by the Task Force on Climate-Related Financial Disclosures (TCFD) have been considered for the third consecutive year in 2025 for Bellevue's sustainability reporting.

We are currently working to identify and assess climate-related risks that may impact our business activities. In the coming years we are planning to revise and expand our reporting on climate-related factors. The recommendations are structured around four thematic areas that represent core elements of how organizations operate: governance, strategy, risk management, and metrics and targets.

Governance	Strategy	Risk Management	Metrics & Targets
Disclose the organization's governance around climate-related risks and opportunities.	Disclose the actual and potential impacts of climate-related risks and opportunities on the organization's businesses, strategy, and financial planning where such information is material.	Disclose how the organization identifies, assesses, and manages climate-related risks.	Disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material.

Source: TCFD, 2025

## Governance

Climate-related opportunities and risks could potentially influence all areas of BB Biotech and its business – both in terms of our own business activities and the portfolio companies. Therefore the ultimate responsibility for this topic lies with BB Biotech's Board of Directors and its dedicated Sustainability and Governance Committee (SGC).

The Investment Management Team is responsible for the implementation of the investment strategy with a focus on sustainability topics as well as overarching principles and policies.

In addition, the Sustainability Working Group is entrusted with managing the implementation and integration of sustainability across all areas of the business. The working group comprises members from various functions, such as Risk Management, Product Management or Legal and Compliance. The group monitors the latest developments on the sustainability front and anticipates their impact on the business model. It supports the Bellevue Executive Board with formulating and developing the sustainability strategy. The Sustainability Working Group is therefore additionally responsible for managing and implementing projects within the business areas/functions and areas of activity.

## Strategy

BB Biotech recognizes that a contribution towards the realization of the objectives set out in the Paris Agreement is required. This can be achieved through the way in which we structure our portfolio. We analyse and manage climate-related risks and show how they influence our investment decisions. As a biotech investor, we naturally apply sector exclusions for controversial industries (e.g. fracking/oil sands, etc.), engage in an active dialogue with the companies or other stakeholders regarding their climate strategy, and exercise our voting rights.

At an operational level, we disclose the emissions resulting from our own business activities in our Sustainability Report. BB Biotech considers sustainability risks to be a critical element of its risk management practices.

## Climate Risk Management

Risks arising from disruptions and shifts that indirectly affect BB Biotech, e.g. through the introduction of climate policy measures involving a transition to a low-carbon economy (e.g. CO<sub>2</sub> levies, emissions or energy efficiency standards, or restrictions on «unsustainable» industries such as coal or oil), severely changing consumer sentiment or disruptive technological breakthroughs.

## Metrics and targets

BB Biotech and the Investment Manager endorses the goals of the Paris climate agreement adopted in December 2015 and supports measures to mitigate global warming. Carbon intensity is measured at the portfolio level at least on a quarterly basis and these readings are compared with the relevant investment universe or the respective benchmark.

Bellevue has been purchasing electricity from renewable sources for its Swiss locations – either directly or otherwise indirectly through regional Guarantees of Origin and is further formalizing the net-zero climate strategy. Goal is to reduce greenhouse gas emissions from our business operations to net-zero by 2050.

## Social practices

Employees are the most important asset for the long-term success of BB Biotech and the Investment Manager. We foster a strong entrepreneurial culture with flat hierarchies, a high level of personal responsibility and flexibility in terms of working hours, workload and location.

Our commitment to treating employees with respect and responsibility is evident in both daily interactions and structured employee evaluations. These evaluations provide a foundation for personal feedback and planning for future development. We actively support targeted training and professional development, both financially and through creating an environment conducive to learning and growth.

The health and safety of our employees, as well as others impacted by our business activities, are of utmost importance. As an employer, we play a crucial role in promoting our employees' well-being through various initiatives, helping them stay healthy and motivated over the long term. Employees are also offered free vaccinations annually, including those for influenza and tick-borne encephalitis.

The added value that BB Biotech generates for its investors is inextricably linked to the professional competence, motivation and high level of identification of the Investment Management Team. Accordingly, we place great emphasis on the careful selection of suitable talent. The suitability of a candidate is usually assessed over several selection stages and assessments. In addition to professional competence, soft skills such as the ability to work in a team and compatibility with corporate values are also assessed. From the employees' point of view, the manageable size of the company and the resulting personal contacts are a key success factor. Criteria such as age, origin and gender must not lead to discrimination.

The Investment Manager Bellevue recruited a total of 16 employees in 2025 across all locations and had a total of 72.8 FTE as at December 31, 2025.

Number of new hires	2025	2024	2023
Switzerland	12	9	6
- thereof men	10	5	3
- thereof women	2	4	3
Europe	1	1	4
- thereof men	–	1	3
- thereof women	1	–	1
Other	3	1	–
- thereof men	2	–	–
- thereof women	1	1	–
<b>Total</b>	<b>16</b>	<b>11</b>	<b>10</b>
- thereof men	12	6	6
- thereof women	4	5	4

<b>By age groups</b>			
>50	2	3	2
30-50	13	7	7
<30	1	1	1
<b>Total</b>	<b>16</b>	<b>11</b>	<b>10</b>
<b>Recruitment rate</b>			
	<b>18.8%</b>	<b>11.4%</b>	<b>9.8%</b>
- thereof men	14.1%	6.2%	5.9%
- thereof women	4.7%	5.2%	3.9%

## Employee development and retention

The development of our employees is of central importance and an integral part of the Sustainability Plan 2030. Lifelong learning is becoming increasingly important. The company organization is designed to enable employees to develop and use their respective professional talents in the best interests of the company's stakeholders, the company and the employee, always taking into account the family and personal environment (e.g. part-time work, IT setup for home office, support for training and development).

Under the supervision of the HR department, employees are offered a wide range of professional development opportunities as well as career and succession planning as part of Bellevue's onboarding and induction process and education and talent management program. The regular institutionalized employee appraisals provide a framework for assessing personal performance and planning further development.

Training all employees on relevant compliance topics (including anti-corruption) is key to ensuring compliance with company-wide compliance requirements. In fiscal year 2025, the following compliance training courses were conducted: Market Conduct (all employees), Code of Conduct (portfolio managers), cross-border (all employees), cyber security (all employees), general compliance/instructions training (all new employees), and online training courses on generative AI and ChatGPT Enterprise (all employees). In addition, all employees complete annual e-learning modules on cyber security.

## Occupational Health and Safety

The health and safety of our employees, as well as of all people affected by our business activities, are of the highest priority for the Bellevue Group. As an employer, we consider it our responsibility to create appropriate conditions and implement targeted measures that make a positive contribution to the physical and mental health of our employees and support them in remaining healthy, motivated, and capable of performing over the long term.

To promote health and well-being, we rely on a combination of preventive measures, health-promoting infrastructure, and a supportive corporate culture. At the Zurich location, employees are offered a free daily breakfast with bread and fruit; beverages as well as coffee and tea are also provided free of charge. In addition, employees receive an annual contribution for fitness activities.

All workplaces are ergonomically designed and equipped with height-adjustable desks and sufficient natural daylight. This helps prevent health-related strain in everyday work and promotes a healthy working environment.

To support preventive healthcare, Bellevue offers employees a free annual flu vaccination, which is administered at the company's headquarters by an external physician. Participation is voluntary and forms part of our preventive health approach.

Team cohesion (“Bellevue Team Spirit”) is actively fostered through regular social events such as summer parties and shared lunchtime barbecues. From our perspective, social interaction and team spirit make an important contribution to mental well-being and a positive working atmosphere.

As an asset manager with a clear focus on the healthcare sector, health is also firmly embedded in our corporate culture. The analysis of and investment in healthcare companies are core components of our investment strategies. Our experts regularly present internally and externally on current developments and challenges in the healthcare sector. Professional exchange on topics such as the increase in lifestyle-related diseases, nutrition, physical activity, and prevention helps to sustainably strengthen health awareness among our employees.

## Remote Work and Flexible Working Models

As a modern employer, the Bellevue Group enables its employees to perform their work partly from home where the function allows. This flexible working model supports the compatibility of professional and private life and contributes to an improved work-life balance.

Employees particularly value the option to work from home due to increased flexibility, the elimination of commuting time, and a more efficient organisation of their working day. At the same time, remote work contributes to employee well-being and to the long-term attractiveness of the Bellevue Group as an employer.

## Working Time Arrangements and Work Organisation

The Bellevue Group places great importance on transparent and reliable working time arrangements that comply with legal requirements while taking into account the differing needs of employees. Working time structures are designed to achieve a balanced relationship between operational requirements and individual flexibility.

Weekly working hours and the organisation of working time are based on the respective functions, responsibilities, and contractual agreements. Flexible working time models enable employees to organise their daily work more independently and support the reconciliation of professional and private life.

Compliance with applicable working and rest time regulations is ensured. Managers bear particular responsibility for appropriate work organisation and a realistic workload within their teams. The aim is to prevent excessive workloads and to promote the sustainable performance and well-being of employees.

## Employee engagement

### Employee information channels

In order to address employees’ increased need for internal information updates, also in 2025 a total of 4 quarterly employee information events were held. Besides the latest operating results, information is given about specific products, new developments, the projects being developed and pursued by individual teams and so on. The presentations are prepared in collaboration with the directly involved employees, which gives them an opportunity to present their specific tasks and related challenges in their own words.

### Employee development

In addition to the annual review, employees have the opportunity to suggest and pursue suitable training and education initiatives (see «Training and education» for further details).

### **Collaboration between executive management teams**

Due to its historically and geographically diverse structure, Bellevue operates with multiple executive management teams. A level of merging and consolidation has now taken place, and interaction has been stepped up through regular meetings.

### Remuneration policy

#### **Within Bellevue, the following overarching principles apply to all compensation:**

Compensation is transparent, comprehensible, fair and appropriate for members of the Board of Directors and Group Executive Management as well as for all employees. All compensation must take balanced account of operational and strategic responsibility, the quality of the work and the workload of the respective function. Compensation shall be commensurate with the function and shall be influenced to a significant extent by the individual achievement of quantitative as well as qualitative targets and by the results of Bellevue. When determining compensation, it must be ensured that it is proportionate and competitive compared to companies in the same labour market and economic sector, and that it is sustainable regardless of the course of business. Serious breaches of internal or external regulations (incl. ESG/sustainability) will lead to a reduction or forfeiture of variable compensation.

Further details and numbers are publicly disclosed in the audited compensation report of Bellevue Group AG as part of the annual report.

### Employee profit participation

In the spirit of identification with the company and the entrepreneurial activities of each employee at his or her level, we give employees across all hierarchical levels a share in the success of their own employer.

For the Investment Management Team of BB Biotech there is a compensation system in place with three components:

1. Competitive fixed salaries in line with asset management industry standards,
2. An allocation of the management fee paid by BB Biotech AG reflecting mid- and long-term success,
3. A long-term incentive plan, fully aligned with shareholders' interests with multi-year performance hurdles, resulting in payments between 0% and 100%.

Furthermore, Bellevue periodically offers an employee share ownership program under which rights to purchase Bellevue Group shares are offered at a discounted purchase price.

The compensation of employees is designed to motivate all employees to perform very well. This approach promotes a long-term performance culture.

### Diversity and Inclusion

The Investment Manager provides equal employment and advancement opportunities to all individuals regardless of age, race, ethnicity, gender, sexuality, disability, religion or other characteristics. That's why we benefit from a diverse workforce, creating a competitive advantage.

With their different perspectives and approaches, experiences, ideas and skills, employees inspire and learn from each other. As a result, the company gains in creativity, innovation and success.

We foster a culture of gender equality and promote a balanced mix of gender and age across all hierarchical levels and functions of the company. Employee compensation is periodically reviewed (every 2 years) for unjustified differences and adjusted if necessary. In

2025, an analysis of salaries was carried out using the federal government's standard software («Logib»). No gender effect was identified.

Both genders should be represented on the Group Executive Board and on the Board of Directors. Discriminatory behavior will not be tolerated and improper conduct will be punished by line managers. To that end, a whistleblowing policy was approved and an internal reporting system created in 2022.

The Board of Directors of Bellevue Group has set itself the goal of continuously increasing the proportion of women at all levels, especially at senior management level (Board of Directors and executive management). Furthermore, the Board of Directors is promoting the development and retention of women in the company. In addition, the company aims to fill vacant positions with women through targeted talent attraction measures.

In 2025, the following activities took place in the area of diversity and equal opportunities:

- To date, no complaints or reports of discrimination have been received via the aforementioned whistleblowing or whistleblower system.

## Governance practices

### Transparency

In accordance with Regulation (EU) 2019/2088 of the European Parliament and the Council of the European Union of November 27, 2019, on sustainability-related disclosures in the financial services sector, Bellevue Asset Management is committed to transparency with respect to:

- Policy for managing sustainability risks
- Adverse sustainability impacts at entity level
- Compensation policies in relation to the integration of sustainability risks
- Adverse sustainability impacts at financial portfolio level
- Promotion of environmental or social characteristics in pre-contractual disclosures
- Sustainable investments in pre-contractual disclosures
- Promotion of environmental or social characteristics and of sustainable investments on websites
- Promotion of environmental or social characteristics and of sustainable investments in periodic reports

### Insider Information Policy

At Bellevue, we strictly protect non-public, price-sensitive information. Employees and representatives are prohibited from using or disclosing insider information for personal or professional advantage. We comply with all applicable laws and regulations on insider trading in order to safeguard market integrity and maintain investor confidence.

### Due Diligence

Bellevue Group AG and its subsidiaries apply appropriate and risk-based due diligence processes to systematically identify, assess, and manage potential adverse impacts of their business activities on environmental, social, and governance (ESG) matters. Due diligence covers the full scope of business operations and includes, in particular, own business activities, investment activities, and relevant business relationships.

Within these processes, potential risks and adverse impacts are analysed, prioritised, and, where possible, prevented, mitigated, or otherwise addressed through appropriate

measures. Findings from due diligence are incorporated into internal policies, decision-making processes, and control mechanisms. Where actual or potential adverse impacts are identified, Bellevue assesses appropriate remedial actions and monitors their implementation.

## Conflicts of Interest

Bellevue is committed to the transparent disclosure of potential or existing conflicts of interest to ensure that reporting and decision-making are carried out objectively and responsibly. We have established mechanisms to identify potential conflicts of interest. All employees and members of the Board of Directors are required to disclose conflicts of interest as soon as they become aware of them. This includes personal interests, financial holdings, family relationships, or other relevant connections that could give rise to a conflict of interest.

Bellevue has issued a “Conflicts of Interest Policy” that sets out the company’s guidelines for dealing with conflicts of interest. The policy aims to protect Bellevue’s reputation as an ethical and fair manager of collective investment schemes and assets of pension institutions, ensure compliance with regulatory requirements, and maintain the trust of clients and business partners.

Any transactions with related parties are disclosed in Note 9 to the consolidated financial statements.

## Whistleblowing

Bellevue strives to comply with all regulatory requirements at all times and to implement them accordingly. To support this purpose, Bellevue expects its employees to speak up when they know of or suspect conduct or incidents that violate laws, regulations or internal directives. Bellevue’s Whistleblowing Platform is a secure web-based solution for internal reporting of Misconduct. The Whistleblowing Platform is hosted and maintained by a thirdparty provider which has no access to the content of reports. In line with its commitment to transparency and good governance, Bellevue’s whistleblowing policy is publicly available on the investment manager’s website under the ‘Policies’ section.

## Client Data Protection

Protecting client data is a key priority for Bellevue and a fundamental basis for trust and long-term client relationships. Compliance with applicable data protection regulations is ensured through clear policies, regular employee training, up-to-date security technologies and annual risk assessments.

Bellevue is not ISO 27001 certified, as it does not provide external IT services; however, its internal IT systems are reviewed annually by several independent audit firms. No data breaches or regulatory sanctions were identified during the reporting periods.

## Policy

### **Sustainability risks**

«Sustainability risks» is defined as an environmental, social or governance event or condition that, if it occurs, could cause an actual or a potential material negative impact on the value of the investment<sup>1</sup>.

Bellevue Asset Management AG and its subsidiaries have integrated sustainability risks into the investment decision-making processes of all their actively managed strategies and associated funds with the aim of identifying, assessing and, if possible and appropriate, mitigating such risks.

While every investment strategy can be exposed to such sustainability risks to varying degrees, the projected impact of sustainability risks on the returns of the investment strategies will depend on the specific investment strategy.

100% of BB Biotech's and more than 90% of Bellevue Asset Management AG's assets under management as at December 31, 2025, are invested in the healthcare sector, which is characterized by lower levels of carbon emissions than the manufacturing, commodities or energy sectors and the broadly diversified global equity indices. Focus on healthcare therefore reduces the sustainability risks.

1 in Regulation (EU) 2019/2088 of the European Parliament and of the Council of the European Union of November 27, 2019 on sustainability-related disclosures in the financial services sector (Sustainable Finance Disclosure Regulation, SFDR)

## ESG investment policy

### ESG framework in portfolio management



Source: Bellevue Asset Management, as at December 31, 2025

## Exclusion criteria

Bellevue Asset Management is committed to complying with internationally recognized standards and consistently exclude companies with serious violations of human rights, the environment, labour standards and involvement in corruption from the investment portfolios it manages. No investments may be made in companies that seriously violate the environment, human rights and business ethics. This is measured by compliance with the principles of the UN Global Compact Compliance, UN Guiding Principles for Business and Human Rights, and standards of the International Labour Organization.

In contrast to exclusions based on violations of global standards, values-based exclusions are based on social, ethical and moral views. Percentages of sales per business segment are defined, that a company may not exceed in ESG-critical business segments such as thermal coal or tobacco production. Issuers whose annual sales exceed the generally accepted tolerance limits defined below are excluded. For BB Biotech and the biotech industry in general, these thresholds are in practice not relevant.

Business area	Revenue threshold	BB Biotech
Controversial weapons	0%	0%
Thermal coal	5%	0%
Fracking/oil sands	5%	0%
Production of tobacco	5%	0%
Sale of tobacco	20%	0%
Adult entertainment	5%	0%
Gambling	5%	0%
Palm oil	5%	0%

The defined turnover limits are based on empirical values with institutional investors and industry experts.

Bellevue Asset Management maintains an exclusion list, which is updated on a quarterly basis. Currently, this list comprises close to 700 issuers that are excluded from all investment universes in the context of direct investments.

## ESG Integration

Environmental, social and governance factors are incorporated into the fundamental assessment of a company and evaluated in terms of their financial risks or opportunities for future share price performance. This gives our portfolio managers a holistic picture of a company.

The environmental area includes, for example, whether a company systematically measures and discloses its environmental footprint. The area of society includes, for example, product quality, data security and employee development. Good governance includes, for example, independence and compensation of the board of directors or business ethics.

As a basis for the integration of sustainable business criteria in the investment decision process, the Investment Manager uses an ESG rating per issuer, which is composed of various sub-scores. The scores are based on data from the independent third-party providers MSCI ESG Research. Their relevance and consequently weighting can vary significantly depending on the industry affiliation.

Over the past year, it has again proven important to interpret aggregated ESG ratings with caution and to critically scrutinize them. Most ESG rating methodologies are based on predefined systematics that do not lead to an objective or «fair» risk assessment in all cases. Especially small-capitalized and young companies, such as those still in the start-up phase, are typically systematically disadvantaged compared to large companies. A lack of human resources and experience in dealing with ESG issues can lead to a poorer sustainability rating. MSCI ESG Research regularly conduct client surveys to address these issues and implement potential methodology improvements.

Our portfolio managers and analysts stand in close contact with our portfolio companies and in many cases may have a more profound fundamental understanding of certain processes with the company than an external ESG rating agency. Accordingly, our portfolio managers take a critical look at potential or alleged «ESG laggards» (rating CCC, B) and repeatedly seek personal discussions with the ESG specialists of our cooperation partner and the companies concerned. Our ESG investment guidelines tolerate an investment in an alleged «ESG laggard» provided that our rationale to do so is clearly explained and documented in detail. Nonetheless, an investment in a so-called «ESG laggard» does under no circumstances qualify as an investment with «sustainable characteristics» nor as a «sustainable investment»

with regards to the calculation of our regulatory ESG investment proportions (c.f. also chapter Proportion of ESG Investments).

## ESG stewardship

As a responsible investor with a long-term focus, BB Biotech supports all measures and initiatives that increase the value of the companies invested in over the long term in the interests of shareholders and investors. This includes engagement activities as well as the exercise of voting and election rights on the occasion of general and shareholders' meetings.

## Engagement

Active management means investing with conviction. We know what we are investing in, and pursue this with great discipline. At Bellevue you will not find any overarching investment committees or a CIO. Working independently in their own product areas, the relevant investment specialist teams are all committed to personal responsibility, respect, and the strength of their own vision. As well as being investment experts, our employees are simultaneously entrepreneurs who participate in the success of clients through their own investments. Active management also stands for constructing high-conviction portfolios based on a bottom-up oriented investment process, which inherently includes not only the decision to allocate a security, but also in many instances to exclude a security for various reasons. The latter is often a result of an in-depth interaction with company representatives, which we would certainly also describe as a type of engagement.

This commitment to active investment management also highlights the importance of engagement as a key element in our ESG framework. Portfolio managers are engaged in an active and constructive dialog with the executives and other relevant stakeholders of portfolio companies on environmental, social and governance issues. All our engagements are conducted along (but not limited to) our predefined list of key ESG issues, which are reviewed periodically and may change in terms of priority as a result of changing dynamics in the field of ESG.

Written records of ESG engagement activities are maintained as part of the regular documentation of conversations with company representatives. In addition, every relevant company interaction is systematically recorded in our proprietary ESG Engagement Tool and as such accessible to all investment team and ESG product management members.

Bellevue Asset Management's ESG Investment Guideline, particularly its section on Stewardship, can be found [here](#).

## ESG-Reporting

Since 2019, Bellevue Asset Management AG has been a signatory of the United Nations Principles for Responsible Investment (UN PRI). PRI reporting is the world's largest responsible investment reporting project. It was developed with investors for investors. Reporting on our sustainability activities and progress is one of the six principles of the UN PRI. Bellevue Asset Management is also a member of Swiss Sustainable Finance Association (SSF).

We fulfil our responsibility in ESG reporting through quarterly ESG factsheets, the ESG section of the Bellevue and BB Biotech websites, Bellevue Asset Management's UN PRI Report as well as regulatory portfolio related ESG reporting, namely EU SFDR Annex IV report.


# Sustainability at BB Biotech AG's portfolio level

The Head Investment Management Team BB Biotech and member of the executive management board at Bellevue Asset Management AG comments as follows:

Our investment process fully implements Bellevue Asset Management's formal ESG investment guidelines and therewith all BB Biotech investments are systematically reviewed for sustainability risks and breaches of elementary human rights (as defined, for example, by UN Global Compact principles). Besides upholding strict exclusion criteria – such as very severe controversies that violate universal norms regarding the environment, human rights or good corporate governance – environmental, social and governance factors are integrated into the fundamental analysis of every company through an ESG integration process in which the associated financial risks or opportunities are evaluated with respect to future share price development. ESG ratings compiled by the global leading ESG research provider MSCI ESG Research are referenced in this process, all the while exercising the necessary prudence and, in some cases, questioning the ESG score.

## Responsible Investing

MSCI ESG Rating distribution (portfolio investments)



Note: Rating based on 92.2% MSCI ESG Research coverage. The aggregated weighted average MSCI ESG rating of all portfolio investments as per 31.12.2025 amounts to a BBB-rating. This BBB-rating must not be confused with the MSCI ESG A rating awarded to BB Biotech AG as a corporate organisation (incl. operations of its asset manager). Source: MSCI ESG Research, Bellevue Asset Management, Data as of December 31, 2025

## Sustainability at BB Biotech AG's portfolio level

Name	MSCI ESG Rating 2024	MSCI ESG Rating 2025	CO2 Intensity <sup>1)</sup> (T/USDm Sales) 2024	CO2 Intensity <sup>1)</sup> (T/USDm Sales) 2025	Portfolio weight as at 31.12.2025
Revolution Medicines	BB	B	49.7	49.7	11.8%
Argenx SE	AA	AA	0.45	2	11.4%
Ionis Pharmaceuticals	BB	AA	5.7	7.3	11.2%
Vertex Pharmaceuticals	AA	AA	2.2	2.3	8.9%
Neurocrine Biosciences	A	AA	68.2	74.1	7.1%
Avidity Biosciences	n.a.	BB	n.a.	32.3	5.6%
Scholar Rock	A	BB	49.7	49.7	5.3%
Alnylam Pharmaceuticals	A	AA	15.4	6	5.2%
Amicus Therapeutics	n.a.	BB	n.a.	74.1	4.5%
Viridian Therapeutics	n.a.	BBB	n.a.	42.7	4.0%
Nuvalent	n.a.	CCC	n.a.	49.7	3.1%
Krystal Biotech	n.a.	B	n.a.	42.7	3.0%
Celldex Therapeutics	A	A	49.6	32.3	2.9%
Immunocore	n.a.	n.a.	–	–	2.9%
Vera Therapeutics	n.a.	–	n.a.	–	2.5%
Relay Therapeutics	BBB	BBB	49.9	42.7	2.1%
Rivus Pharmaceuticals	n.a.	n.a.	–	–	1.6%
Jade Biosciences	n.a.	n.a.	–	–	1.5%
Edgewise Therapeutics	BBB	BBB	62.1	62.1	1.1%
Maze Therapeutics	n.a.	–	n.a.	–	1.1%
Tango Therapeutics	n.a.	BBB	n.a.	42.7	1.0%
Annexon	n.a.	BBB	49.9	49.7	0.8%
Wave Life Sciences	n.a.	BBB	49.9	42.7	0.7%
Galecto Inc.	n.a.	–	n.a.	–	0.7%
<b>Portfolio of BB Biotech</b>	<b>BBB</b>	<b>BBB</b>	<b>31.9</b>	<b>29.7</b>	<b>100.0%</b>

<sup>1</sup> Scope 1+2, based on 100% portfolio exposure

The MSCI ESG rating of the average weighted portfolio positions remained constant at a BBB rating. Select core positions such as Ionis, Alnylam, Neurocrine improved their ratings, whereas Revolution Medicines and Scholar Rock saw a downgrading by MSCI ESG. During the period under review MSCI ESG initiated coverage for Annexon with a solid BBB rating.

Carbon intensity is measured at the portfolio level at least on a quarterly basis. With a carbon risk of 29.7 tons of CO<sub>2</sub> per million USD revenues BB Biotech's overall carbon intensity remains at the low end and is slightly lower versus the previous year (31.9 tons). For a low carbon industry such as biotechnology, carbon reduction is not the predominant objective with regards to long-term sustainability goals, which is also reflected in the MSCI ESG rating for the biotechnology sector where the weights for the individual categories are distributed as follows: Environment (10%), Social (55%), Governance (35%).

## CO<sub>2</sub>-intensity (T CO<sub>2</sub>E/USD mn Revenue)



Source: MSCI ESG Research, Bellevue Asset Management, Data as of December 31, 2025

## Biodiversity-sensitive areas and related controversies

Based on the applied screening criteria by MSCI ESG, none of our portfolio companies has been identified as having operations in or near biodiversity-sensitive areas that are assessed to potentially negatively affect local biodiversity without an impact assessment, nor has any company been involved in controversies with severe impacts on local biodiversity.

## Stewardship through engagement and active voting

### a) Engagement


Our stewardship duties encompass an active and constructive dialogue with our portfolio companies on environmental, social and governance issues. In case of indications of substantial controversies in the area of ESG, these are raised constructively within the framework of the corporate dialogue and progress (e.g. strategy and process adjustments, improvement of ESG rating) is documented over time. Engagement activities must also be placed in the context of materiality and proportionality. Engagement activities can take place to varying degrees depending on the size of the investment strategies involved, the capitalization of the company, the stage of development of the company, and other factors. Accordingly, in addition to our regular interactions with company executives and other stakeholders, we focused on two formal ESG engagements in 2025. One of which was closed due to divestment of the company, the second was newly initiated during the reporting period. Both active engagements concerned corporate governance issues («G») and one is focused on “human capital development” («S»).

### b) Proxy voting

The second stewardship element concerns our actively exercising our voting rights at AGM's through proxy voting. In order to extract long-term investor value added through active portfolio management we keep a constant dialogue also on sustainability matters with companies senior management which is eventually reflected in our voting decisions. Bellevue Asset Management's and BB Biotech AG's Board of Directors take our voting obligations very seriously and respective structures are in place to ensure that we vote in all shareholder meetings.

Material voting items on the AGM agenda such as board composition, compensation or incentive schemes are evaluated on a case-by-case-basis, supported by research data of Institutional Shareholder Services group (ISS). The Investment Management Team receives voting recommendations and research material from ISS. ISS brings more than 30 years of experience and global resources to serve approximately 1 500 institutional clients globally. ISS makes sure to maintain market leading stewardship practices. Should we vote against a proposed agenda item, we would usually have a prior discussion and elaboration of our rationale and understanding with members of the company management or the Board of Directors.

During 2025 we voted at 22 of 24 votable meetings covering 141 resolutions (vs. 27 votable meetings and 171 resolutions in 2024). In 114 cases we thereby voted in line with management recommendations (vs. 156 votes in 2024) and for 11 resolutions voted against management recommendation (vs. 15 votes in 2024).



Source: Bellevue Asset Management

## Proportion of ESG investments

Referring to the EU SFDR 2019/2088 Regulatory Product Disclosures (Art. 10)/Commission Delegated Regulation (EU) 2021/1253 to MiFID II, Bellevue distinguishes investments with «sustainable characteristics» and, as a subset of which, «sustainable investments».

### a) Share of investments with sustainable characteristics

In accordance with EU SFDR 2019/2088, Bellevue Asset Management introduced the following set of ESG criteria that must be met by a minimum portfolio proportion of 50% for BB Biotech:

- Compliance with global norms – i.e. no severe violations against standards and principles of the UN Global Compact, the UN Guiding Principles for Business and Human Rights, and Conventions 1 and 2 of the International Labour Organization (ILO).
- Investments in ethically or morally controversial business areas are limited by considering predefined revenue thresholds (in practice not relevant for the biotech industry, those thresholds are nevertheless formally monitored).
- Minimum ESG Rating of BB or higher to assure adequate level of «Good governance» on E, S and G
- Stewardship through constructive corporate dialogue (engagement) and the exercise of voting rights (proxy voting)

In principle, we aim to invest all assets of BB Biotech in investments with «Sustainable characteristics» but there is not always a sufficient amount of ESG-data available in any market cap segment, particularly in the field of small and mid-cap companies. Additionally, some companies may not have an ESG rating yet or the current rating does not correspond with our view on the most relevant sustainability aspects.

### b) Share of sustainable investments


The concept of «Sustainable investments» imposes more stringent restrictions on above ESG characteristics by introducing a positive contribution to an environmental and/or a social objective while do not significant harm any of these objectives («DNSH»). Furthermore, the invested portfolio companies must apply practices of good corporate governance. For an investment to qualify as a «sustainable investment», the Investment Manager applies the 17 UN Sustainable Development Goals (SDGs). These sustainable development goals are

general, universal goals for all UN member states, which were adopted in September 2015 as the successor to the Millennium Goals. The entire world population should be able to live in a fairer, more prosperous and more peaceful society by 2030.

As already elaborated above (chapter UN SDG) ESG research provider MSCI ESG measures the degree of alignment with each of the SDGs. A positive contribution to an environmental or social objective hence requires a company to exhibit a positive alignment with at least one of the 17 UN SDGs while not affecting any other SDG negatively.

Investments are assigned to the «sustainable investment» proportion if, on the one hand, they exhibit a positive target contribution as described above and, on the other hand, they meet the criteria for «investments with sustainable characteristics» described above, which also ensures that good governance practices are applied. In addition, the most important adverse sustainability impact indicators (PAI) are explicitly or implicitly considered in this process. In the case of explicit consideration, thresholds are determined for each PAI criterion (where possible), which define the point at which a particular PAI criterion has a «material adverse impact» on a sustainability factor. If a «material adverse impact» is measured for an issuer, the issuer concerned cannot be classified as a sustainable investment, regardless of whether the issuer makes positive contributions to one of the 17 UN sustainability goals or not. The threshold values are derived empirically from empirical values and formally approved by the Bellevue ESG Working Group. In the case of implicit consideration, characteristics of the relevant PAI criteria are included in the MSCI ESG rating process and thus lead to indirect consideration by determining minimum ratings, which are used to calculate the minimum quotas.

In accordance with European MiFID regulation, a corresponding minimum proportion of sustainable investments has been defined and set at 25% for BB Biotech AG. The overall regulatory ESG breakdown for the BB Biotech portfolio as at December 31, 2025, is summarized below:



Source: Bellevue Asset Management, MSCI ESG Inc.

# Annex

## GRI content index with reference

GRI content index	
Statement of use	BB Biotech AG has reported the information cited in this GRI content index for the period 01.01.2025 – 31.12.2025 with reference to the GRI Standards.
GRI used	GRI 1: Foundation 2021

GRI Standard	Disclosure	Location in Annual Report
GRI 2: General Disclosures 2021	2-1 Organizational details	About us
	2-2 Entities included in the organization's sustainability reporting	Sustainability Governance
	2-3 Reporting period, frequency and contact point	About us: Corporate calendar / Contact
	2-6 Activities, value chain and other business relationships	About us
	2-7 Employees	Social Practices
	2-9 Governance structure and composition	Corporate Governance
	2-10 Nomination and selection of the highest governance body	Corporate Governance: Board of Directors
	2-11 Chair of the highest governance body	Corporate Governance: Board of Directors
	2-19 Remuneration policies	Remuneration Report: Remuneration of the members of the Board of Directors
	2-20 Process to determine remuneration	Remuneration Report: Remuneration of the members of the Board of Directors
	2-22 Statement on sustainable development strategy	Sustainability Strategy
	2-25 Processes to remediate negative impacts	Environmental practices
	2-26 Mechanisms for seeking advice and raising concerns	Social Practices: Diversity and Inclusion
	2-28 Membership associations	Environmental practices: Key climate-relevant memberships
2-29 Approach to stakeholder engagement	Stakeholder Engagement and Material ESG Topics	
GRI 3: Material Topics 2021	3-1 Process to determine material topics	Stakeholder Engagement and Material ESG Topics
	3-2 List of material topics	Stakeholder Engagement and Material ESG Topics: Material ESG topics identified
	3-3 Management of material topics	Stakeholder Engagement and Material ESG Topics: Material ESG topics identified
GRI 201: Economic Performance 2016	201-1 Direct economic value generated and distributed	Financial report
GRI 302: Energy 2016	302-1 Energy consumption within the organization	Environmental Practices: Energy consumption
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Environmental Practices: Measurement of environmental indicators
	305-2 Energy indirect (Scope 2) GHG emissions	Environmental Practices: Measurement of environmental indicators

	305-3 Other indirect (Scope 3) GHG emissions	Environmental Practices: Measurement of environmental indicators
	305-4 GHG emissions intensity	Environmental Practices: Total emissions at a glance
	305-5 Reduction of GHG emissions	Environmental Practices: CO2 emissions
GRI 306: Waste 2020	306-1 Waste generation and significant waste-related impacts	Environmental Practices: Waste management and recycling
	306-2 Management of significant waste-related impacts	Environmental Practices: Waste management and recycling
GRI 401: Employment 2016	401-1 New employee hires and employee turnover	Social Practices
	401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees	Social Practices: Employee development and retention
GRI 405: Diversity and Equal Opportunity 2016	405-1 Diversity of governance bodies and employees	Board of Director level: Diversity and inclusion; Social Practices: Diversity and inclusion